Industry News

BioTelemetry disclosed on Tuesday the launch of a strategic foetal health technology partnership with Bloom Technologies. Pursuant to the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license the latter's proprietary telemetry technology to commercialise a consumer oriented prenatal health sensor, which will collect and deliver a wide variety of prenatal data to expectant mothers that can be shared with their..."/>
BioTelemetry to grant license to its proprietary technology to Bloom Technologies for prenatal market
Laboratory Corporation of America Holdings reported on Tuesday the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom. On 9 August 2016, LabCorp and its wholly owned subsidiary Savoy Acquisition Corp commenced a tender offer for all of the outstanding common shares of Sequenom, including the associated preferred stock purchase rights, for..."/>
LabCorp passes antitrust review for acquisition of Sequenom
Zimmer Biomet Holdings declared on Tuesday a cash dividend of USD0.24 per share for the third quarter of 2016.. This dividend is payable on or about 28 October 2016, to stockholders of record at the close of business as of 23 September 2016.. According to the company, the future declarations of dividends are subject to approval of the board of directors and may be adjusted as business needs or market conditions change."/>
Zimmer Biomet's board authorises USD0.24 per share dividend for Q3 2016
TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for the Company’ s oral, next generation PI3K Delta inhibitor, TGR-1202, for the treatment of patients with chronic lymphocytic leukemia. TGR-1202 is currently being evaluated in the UNITY-CLL Phase 3 Trial for patients with both frontline and previously treated CLL.."/>
TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Canopy Growth Corporation announced that it has closed its previously announced short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 9,453,000 common shares in the capital of the..."/>
Canopy Growth Corporation completes previously announced bought deal financing, including over-allotment, for $34.5 Million
SCYNEXIS, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the Company’ s novel triterpenoid broad-spectrum antifungal agent, SCY-078, for the treatment of invasive Aspergillus infections.. The orphan drug designation of SCY-078 provides seven years of market exclusivity in the U.S. following FDA approval of an NDA for the orphan designated indication."/>
SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
Patient Home Monitoring, a healthcare service company with operations in the US, announced today that it has posted its financial results for the third quarter of fiscal 2016 and the Company continues to execute on the strategic plan of integrating and optimizing the business units for profitability growth."/>
Patient Home Monitoring Posts Third Quarter Financials and Updates Ongoing Integration Activities
Amedica Corporation, an innovative biomaterial company that develops and commercializes silicon nitride as a platform for biomedical applications, is pleased to announce the U.S. Food and Drug Administration clearance of expanded Valeo ® II Lateral Lumbar sizes. The additional sizes of the Valeo II LL interbody fusion device will be commercially available August 29, 2016.."/>
Amedica Receives FDA Clearance for Additional Valeo(R) II Lateral Lumbar Interbody Fusion Device Offerings
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global pharmaceutical company to provide Fluorescence in Situ Hybridization testing services for a clinical study the pharmaceutical company is conducting in prostate..."/>
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer, effective August 22, 2016. Young reports to Steve Davis, ACADIA’ s President and Chief Executive Officer. This Smart News Release features multimedia."/>
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
JRP Group to set a change of direction in motion after two months of share price falls. The annuity provider had been the worst faller on the market since the EU referendum; its share price had fallen more than 40 pc from June 23 to when the FTSE opened yesterday. But a confident update helped to allay investors' fears."/>
Daily Mail, London, market report column [Daily Mail, London]
Vocera Communications, Inc.. Amendola will provide a broad range of public relations and content services that promote Vocera's mission to break down communication barriers and improve the healthcare experience for patients,..."/>
Vocera Taps Amendola for Public Relations, Social Media, and Content Marketing Strategy & Execution
WellCare Health Plans, Inc., awarded micro-grants to two nonprofit community-based organizations in Kentucky that provide pregnancy-related support services. The grants, totaling $2,000, support the Children, Inc.' s Youth Families..."/>
WellCare of Kentucky Gives Micro-Grants to Community-Based Organizations that Provide Pregnancy-Related Support Services
Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that Akorn’ s CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference.. Event: Morgan Stanley Healthcare Conference Date: September 13, 2016 Time: 12:20 p.m. ET Location: New York, NY. The fireside chat will be webcast live and available on the“ Events& Presentations” page in the Investor Relations section of the Company’ s website at..."/>
Akorn to Present at Morgan Stanley Global Healthcare Conference
Skyline Medical Inc., developer of the innovative STREAMWAY ® waste fluid disposal system for medical applications, reports that Glass, Lewis& Co., Inc. recommends that stockholders vote FOR management proposals to 1) increase the number of authorized shares of common stock to 200,000,000 from 100,000,000 and 2) effect a reverse stock split of its common stock at a ratio of between one-for-two and one-for-25 and a proportionate decrease in the number..."/>
Leading Proxy Advisory Firm Glass, Lewis Recommends Stockholders Vote FOR Skyline Medical Management Proposals
Boston Scientific Corporation is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will participate in a 30- minute question-and-answer-session with the host analyst beginning at approximately 9:20 a.m. EDT. A live webcast of the..."/>
Boston Scientific To Participate In Wells Fargo 2016 Healthcare Conference
Exelixis, Inc. today announced that it has called for redemption approximately $48.1 million of its 4.25% Convertible Senior Subordinated Notes due 2019, representing all remaining notes outstanding. The redemption will be made in accordance with the terms of the indenture governing the notes and the terms of the redemption notice. Any notes outstanding on November 2, 2016 will be redeemed in cash for 100% of the principal amount thereof, plus..."/>
Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
Biomerica Inc. today announced that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "BMRA" on August 26, 2016. The Company's common stock will continue to trade as "BMRA" on the OTCQB until the market close on August 25, 2016.. "Uplisting to Nasdaq represents a milestone for Biomerica as we continue our progress in the commercialization of our new IBS diagnostic..."/>
Biomerica Approved for Listing on the Nasdaq Capital Market
OraSure Technologies reported on Tuesday that it has won a contract, valued at up to USD16.6m, to advance its rapid Zika tests. This funding was awarded by the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority. The company said the six-year, multi-phased agreement includes an initial commitment of USD7.0m and options for up to an..."/>
OraSure secures up to USD16.6m BARDA funding to advance rapid Zika tests
WellCare Health Plans stated on Tuesday that Larry Anderson intends to step down as its senior vice president and chief human resources officer on 1 October 2016.. Effective 22 August 2016, Anderson is no longer the company's executive officer, but will continue to assist with the transition of his duties and responsibilities. However, Michael Yount, the company's senior vice president and chief compliance officer, will assume the SVP& HR..."/>
WellCare reports planned resignation of SVP Larry Anderson
WellCare Health Plans reported on Tuesday that it has elected Rhonda Mims as its senior vice president and chief public affairs officer. Effective immediately, Mims will oversee the development and implementation of the company's strategic communications, public policy, corporate social responsibility, philanthropy, diversity and inclusion and employee volunteerism, reporting to its CEO Ken Burdick. Most recently, Mims has served as the managing..."/>
WellCare appoints Rhonda Mims as chief public affairs officer
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that the Company will present at two investor conferences in September:. September 7, 2016– Baird 2016 Global Healthcare Conference in New York at 3:10 p.m. ET September 12, 2016– Morgan Stanley 2016 Global Healthcare Conference in New York at 3:40 p.m. ET."/>
Henry Schein To Present At Two Investor Conferences In September

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary625 Articles
Information Technology577 Articles
Financials475 Articles
Health Care334 Articles
Industrials313 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.